[go: up one dir, main page]

ECSP13012630A - 4 - (5-ciano-pirazol-1-il)-derivados de piperidina como - Google Patents

4 - (5-ciano-pirazol-1-il)-derivados de piperidina como

Info

Publication number
ECSP13012630A
ECSP13012630A ECSP13012630A ECSP13012630A EC SP13012630 A ECSP13012630 A EC SP13012630A EC SP13012630 A ECSP13012630 A EC SP13012630A EC SP13012630 A ECSP13012630 A EC SP13012630A
Authority
EC
Ecuador
Prior art keywords
pirazol
ciano
piperidine derivatives
protein
receptor coupled
Prior art date
Application number
Other languages
English (en)
Inventor
Michael John Munchhof
Ralph Pelton Robinson
Kim Francis Mcclure
Vicent Mascitti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45418722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012630(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP13012630A publication Critical patent/ECSP13012630A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen compuestos que modulan la actividad del receptor GPR119 acoplado a la proteína G y sus usos para el tratamiento de enfermedades relacionadas con la modulación del receptor GPR119 acoplado a la proteína G en animales.
ECSP13012630 2010-11-23 2013-05-20 4 - (5-ciano-pirazol-1-il)-derivados de piperidina como ECSP13012630A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41644110P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
ECSP13012630A true ECSP13012630A (es) 2013-07-31

Family

ID=45418722

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012630 ECSP13012630A (es) 2010-11-23 2013-05-20 4 - (5-ciano-pirazol-1-il)-derivados de piperidina como

Country Status (27)

Country Link
EP (1) EP2643310A1 (es)
JP (1) JP2013543885A (es)
KR (1) KR20130083915A (es)
CN (1) CN103298801A (es)
AP (1) AP2013006809A0 (es)
AR (1) AR088121A1 (es)
AU (1) AU2011333427A1 (es)
BR (1) BR112013011865A2 (es)
CA (1) CA2814231A1 (es)
CL (1) CL2013001054A1 (es)
CO (1) CO6801716A2 (es)
CR (1) CR20130139A (es)
CU (1) CU20130059A7 (es)
DO (1) DOP2013000102A (es)
EA (1) EA201370118A1 (es)
EC (1) ECSP13012630A (es)
GT (1) GT201300135A (es)
MA (1) MA34805B1 (es)
MX (1) MX2013004083A (es)
NI (1) NI201300044A (es)
PE (1) PE20140409A1 (es)
PH (1) PH12013500677A1 (es)
SG (1) SG189830A1 (es)
TW (1) TWI433843B (es)
UY (1) UY33742A (es)
WO (1) WO2012069948A1 (es)
ZA (1) ZA201302362B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103958495B (zh) 2011-06-09 2018-06-22 理森制药股份公司 作为gpr-119的调节剂的化合物
JP2015522080A (ja) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
CN104592120A (zh) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 一种环丙基酰肼和甲氧苯类gpr119激动剂、制备方法及其用途
CN104892517A (zh) * 2015-02-13 2015-09-09 佛山市赛维斯医药科技有限公司 酰肼类化合物、其制备方法及用途
CN104610151A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 含酰肼和烷氧苯类结构的化合物、其制备方法及用途
EP3416959B1 (en) 2016-02-18 2021-05-12 Syngenta Participations AG Pesticidally active pyrazole derivatives
CN106631992B (zh) * 2017-01-05 2019-01-18 桑迪亚医药技术（上海）有限责任公司 一种4-氧-3,4-二氢-2h-吡啶-1-甲酸叔丁酯的合成方法
CN115925702B (zh) * 2022-12-14 2025-04-25 江西凌富生物科技有限公司 一种咪唑并[4,5-c]吡啶衍生物的提纯方法及其咪唑并[4,5-c]吡啶衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014910A2 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
US20090270404A1 (en) * 2008-03-31 2009-10-29 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
CN102459222B (zh) * 2009-06-05 2014-06-04 辉瑞大药厂 用作gpr119 调节剂的l-(哌啶-4-基)-吡唑衍生物

Also Published As

Publication number Publication date
KR20130083915A (ko) 2013-07-23
CR20130139A (es) 2013-06-28
UY33742A (es) 2012-06-29
TW201300373A (zh) 2013-01-01
GT201300135A (es) 2015-02-19
CO6801716A2 (es) 2013-11-29
BR112013011865A2 (pt) 2016-08-23
AU2011333427A1 (en) 2013-04-11
TWI433843B (zh) 2014-04-11
JP2013543885A (ja) 2013-12-09
MA34805B1 (fr) 2014-01-02
CA2814231A1 (en) 2012-05-31
SG189830A1 (en) 2013-06-28
EP2643310A1 (en) 2013-10-02
PH12013500677A1 (en) 2013-05-06
WO2012069948A1 (en) 2012-05-31
CU20130059A7 (es) 2013-06-28
NI201300044A (es) 2013-08-01
PE20140409A1 (es) 2014-03-23
CN103298801A (zh) 2013-09-11
DOP2013000102A (es) 2013-07-15
AR088121A1 (es) 2014-05-14
MX2013004083A (es) 2013-06-13
ZA201302362B (en) 2014-06-25
AP2013006809A0 (en) 2013-04-30
CL2013001054A1 (es) 2013-09-27
EA201370118A1 (ru) 2013-12-30

Similar Documents

Publication Publication Date Title
ECSP13012630A (es) 4 - (5-ciano-pirazol-1-il)-derivados de piperidina como
CU20110225A7 (es) Derivados de l-(piperidin-4-il)-pirazol como moduladores de gpr 119
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
ECSP12011720A (es) Compuestos heterocíclicos y usos de los mismos
MX378131B (es) Compuestos y sus usos para modular la hemoglobina.
MX351028B (es) Determinadadas entidades, composiciones y metodos quimicos.
CR20110686A (es) Pirimidinonas como ihnibidores de pi3k
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
UY35596A (es) Compuestos para la modulación de quinasas, y sus indicaciones
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
GT201400290A (es) Carboxamidas heterociclicas fungicidas
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
CR20140476A (es) Agentes para tratar transtornos que implican la modulación de receptores de rianodina
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
BR112015012907A2 (pt) composição de cuidado pessoal
BR112015008524A2 (pt) formulações de eletrólitos para aquecedor portátil ativado por oxigênio
BRPI1011912A2 (pt) l-serina para uso como medicamento para prevenir e/ou tratar uma reação inflamatória da pele.
GT201400179A (es) Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio
UY34609A (es) Motivos de interacción de transactivación en plantas y sus usos
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
UY34755A (es) Agentes para el control de la glycaspis brimblecombei
UY34752A (es) Agentes para el control de la chinche del eucalipto
UA101110C2 (en) L-(piperidin-4-yl)-pyrazole derivatives as gpr119 modulators